PDL BioPharma (PDLI) Misses Q3 EPS by 21c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
PDL BioPharma Reports 2019 Third Quarter Financial Results
November 6, 2019 4:05 PM ESTINCLINE VILLAGE, Nev., Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2019:
Third Quarter Financial Highlights
Total revenues were $44.2 million, including $20.3 million in product revenue and $23.9 million in revenue from royalty rights - change in fair value. LENSAR revenues were $8.1 million, up 22% over the prior-year period. U.S. market share for branded Tekturna and authorized generic of Tekturna remained steady at approximately 73%. Net cash royalties from all... More